- Home
- RAMP vs TARS Comparison
RAMP vs TARS Comparison
Compare RAMP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- TARS
- Stock Information
- Founded
- RAMP 2018
- TARS 2016
- Country
- RAMP United States
- TARS United States
- Employees
- RAMP N/A
- TARS N/A
- Industry
- RAMP EDP Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- RAMP Technology
- TARS Health Care
- Exchange
- RAMP Nasdaq
- TARS Nasdaq
- Market Cap
- RAMP 1.8B
- TARS 1.7B
- IPO Year
- RAMP 1987
- TARS 2020
- Fundamental
- Price
- RAMP $28.38
- TARS $57.63
- Analyst Decision
- RAMP Buy
- TARS Strong Buy
- Analyst Count
- RAMP 7
- TARS 7
- Target Price
- RAMP $39.00
- TARS $67.14
- AVG Volume (30 Days)
- RAMP 769.2K
- TARS 658.2K
- Earning Date
- RAMP 11-05-2025
- TARS 08-06-2025
- Dividend Yield
- RAMP N/A
- TARS N/A
- EPS Growth
- RAMP 147.00
- TARS N/A
- EPS
- RAMP 0.22
- TARS N/A
- Revenue
- RAMP $764,441,000.00
- TARS $295,521,000.00
- Revenue This Year
- RAMP $10.65
- TARS $33,170.29
- Revenue Next Year
- RAMP $8.70
- TARS N/A
- P/E Ratio
- RAMP $147.94
- TARS N/A
- Revenue Growth
- RAMP 12.16
- TARS 254.45
- 52 Week Low
- RAMP $22.82
- TARS $27.18
- 52 Week High
- RAMP $36.08
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- RAMP 49.74
- TARS 69.92
- Support Level
- RAMP $26.89
- TARS $57.00
- Resistance Level
- RAMP $28.15
- TARS $59.76
- Average True Range (ATR)
- RAMP 0.67
- TARS 1.74
- MACD
- RAMP 0.31
- TARS -0.26
- Stochastic Oscillator
- RAMP 85.66
- TARS 67.78
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.